Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

Like Comment

GLP-1 receptor agonists are an established therapy in patients with type 2 diabetes; however, their role in type 1 diabetes remains to be determined.Determine efficacy and safety of once-weekly albiglutide 30mg (up-titration to 50mg at week 6) versus placebo together with insulin in patients with new-onset type 1 diabetes and residual insulin production.52-week, randomized, phase 2 study (NCT02284009).A prespecified Bayesian approach, incorporating placebo data from a prior study, allowed for 3:1 (albiglutide:placebo) randomization. The primary endpoint was 52-week change from baseline in mixed meal tolerance test (MMTT) stimulated 2-hour plasma C-peptide area under the curve (AUC). Secondary endpoints included metabolic measures and pharmacokinetics of albiglutide.12/17 (70.6%, placebo) and 40/50 (80.0%, albiglutide) patients completed the study. Within our study, mean (SD) change from baseline to week 52 in MMTT-stimulated 2-hour plasma C-peptide AUC was -0.16 nmol/L (0.366) with placebo and -0.13 nmol/L (0.244) with albiglutide. For the primary Bayesian analysis (including prior study data) the posterior treatment difference (95% credible interval) was estimated at 0.12 nmol/L (0-0.24);the probability of a difference =0.2 nmol/L between treatments was low (0.097). A transient significant difference in maximum C-peptide was seen at week 28. Otherwise, no significant secondary endpoint differences were noted. . On-therapy adverse events were reported in 82.0% (albiglutide) and 76.5% (placebo) of patients.In newly diagnosed patients with type 1 diabetes, albiglutide 30‒50 mg weekly for 1 year had no appreciable effect on preserving residual β-cell function versus placebo.

Click here to read the full article @ The Journal of clinical endocrinology and metabolism
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
0 Following

No comments yet.